What is Jazz Pharmaceuticals PLC's stock symbol?
Jazz Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "JAZZ."
Where is Jazz Pharmaceuticals PLC's stock going? Where will Jazz Pharmaceuticals PLC's stock price be in 2017?
17 brokers have issued 12-month target prices for Jazz Pharmaceuticals PLC's shares. Their predictions range from $148.00 to $210.00. On average, they expect Jazz Pharmaceuticals PLC's stock price to reach $180.29 in the next year.
When will Jazz Pharmaceuticals PLC announce their earnings?
Jazz Pharmaceuticals PLC is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
What are analysts saying about Jazz Pharmaceuticals PLC stock?
Here are some recent quotes from research analysts about Jazz Pharmaceuticals PLC stock:
- Mizuho analysts commented, "We remain bullish on the stock in front of a widely anticipated Xyrem settlement and pipeline catalysts in 1H:17. Jazz has also retained M&A capacity while many of its peers remain overlevered. We are modeling 4Q:16 revenue of $399.8M and EPS of $2.73 relative to consensus estimates $398.9M and $2.65 and the implied guidance ranges of $394-$439M and $2.44-$2.84. We note that Jazz pre-announced at a recent investor conference, indicating that it expects to meet 2016 revenue guidance. We reiterate our Buy rating and raise our PT to $152 from $127." (2/21/2017)
Cantor Fitzgerald analysts commented, "Xyrem patent litigation court date could be around the corner. A trial is scheduled for May 1 and management believes it is likely that the proceeding will commence on that date. Before then, however, a Markman hearing may be held related to a recent Orange Book-listed patent." (1/12/2017)
According to Zacks Investment Research, "Jazz reported better-than-expected earnings in Q3 while revenue fell short of the estimate. Jazz’s sleep disorder drug Xyrem is the only FDA approved product for both cataplexy and EDS. Its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. In October, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos and plans to finish it in early 2017. We believe Vyxeos has multi-million dollar potential. However, Xyrem, is facing patent challenges and some of Xyrem’s patents are undergoing inter partes review. Jazz has also been facing challenges in building sufficient inventory levels for Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions in certain markets, including the U.S., from time to time." (11/14/2016)
Barclays PLC analysts commented, "We think JAZZ’s 2Q earnings report should be viewed in the context of the future of JAZZ rather than its present form. Xyrem remains JAZZ’s biggest product, while growing nicely as maturing which mgmt implicitly acknowledged by noting a slowing in rates of narcolepsy diagnosis. Xyrem revenues came in at $281M, below our $286M but above consensus at $279. More importantly, the Defitelio US launch posted strong revenues of $9.5M, with global revenues of $33M. The strength of the U.S. launch was a good sign for the product’s potential here, but we think JAZZ deserves credit for the improvement in Europe following sales mgmt changes. EPS of $2.63 came in below our $2.90 and consensus at $2.80, though the shortfall is largely explained by non-GAAP tax changes to reflect recent SEC guidance; JAZZ’s cash taxes are unchanged. The tax change reduced 2Q EPS by $0.19 on an apples-to-apples basis. JAZZ updated EPS guidance to $9.90-$10.30, down from the prior $11.10-$11.50, which reflects the change in tax treatment ($0.55), expenses related to Celator ($0.55) as well as supply constraints for Erwinase and higher R&D expense for JZP-110 ($0.10)." (8/10/2016)
Who owns Jazz Pharmaceuticals PLC stock?
Jazz Pharmaceuticals PLC's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (12.47%), Renaissance Technologies LLC (2.61%), FIL Ltd (2.04%), Janus Capital Management LLC (1.67%), Tourbillon Capital Partners L.P. (1.38%) and State Street Corp (1.31%). Company insiders that own Jazz Pharmaceuticals PLC stock include Bruce C Cozadd, Heather Ann Mcsharry, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper.
Who sold Jazz Pharmaceuticals PLC stock? Who is selling Jazz Pharmaceuticals PLC stock?
Jazz Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FIL Ltd, Fiera Capital Corp, Marshall Wace LLP, Asset Management One Co. Ltd., State Street Corp, J. Goldman & Co LP and Brown Capital Management LLC. Company insiders that have sold Jazz Pharmaceuticals PLC stock in the last year include Bruce C Cozadd, Heather Ann Mcsharry, Karen J Wilson, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham, Russell J Cox and Seamus Mulligan.
Who bought Jazz Pharmaceuticals PLC stock? Who is buying Jazz Pharmaceuticals PLC stock?
Jazz Pharmaceuticals PLC's stock was acquired by a variety of institutional investors in the last quarter, including Tourbillon Capital Partners L.P., Renaissance Technologies LLC, Orbimed Advisors LLC, Clough Capital Partners L P, Perceptive Advisors LLC, AQR Capital Management LLC, A.R.T. Advisors LLC and Lumina Fund Management LLC. Company insiders that have bought Jazz Pharmaceuticals PLC stock in the last two years include Karen L Smith and Kenneth W O'keefe.
How do I buy Jazz Pharmaceuticals PLC stock?
Shares of Jazz Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Jazz Pharmaceuticals PLC stock cost?
One share of Jazz Pharmaceuticals PLC stock can currently be purchased for approximately $134.95.